EPIX
Price
$1.70
Change
-$0.01 (-0.58%)
Updated
Jun 6, 04:15 PM (EDT)
Capitalization
75.9M
61 days until earnings call
LXRX
Price
$0.76
Change
+$0.04 (+5.56%)
Updated
Jun 6, 04:29 PM (EDT)
Capitalization
261.38M
55 days until earnings call
Interact to see
Advertisement

EPIX vs LXRX

Header iconEPIX vs LXRX Comparison
Open Charts EPIX vs LXRXBanner chart's image
ESSA Pharma
Price$1.70
Change-$0.01 (-0.58%)
Volume$6.31K
Capitalization75.9M
Lexicon Pharmaceuticals
Price$0.76
Change+$0.04 (+5.56%)
Volume$3.67K
Capitalization261.38M
EPIX vs LXRX Comparison Chart
Loading...
EPIX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EPIX vs. LXRX commentary
Jun 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EPIX is a StrongBuy and LXRX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 07, 2025
Stock price -- (EPIX: $1.71 vs. LXRX: $0.72)
Brand notoriety: EPIX and LXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EPIX: 30% vs. LXRX: 122%
Market capitalization -- EPIX: $75.9M vs. LXRX: $261.38M
EPIX [@Biotechnology] is valued at $75.9M. LXRX’s [@Biotechnology] market capitalization is $261.38M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EPIX’s FA Score shows that 1 FA rating(s) are green whileLXRX’s FA Score has 1 green FA rating(s).

  • EPIX’s FA Score: 1 green, 4 red.
  • LXRX’s FA Score: 1 green, 4 red.
According to our system of comparison, LXRX is a better buy in the long-term than EPIX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EPIX’s TA Score shows that 5 TA indicator(s) are bullish while LXRX’s TA Score has 5 bullish TA indicator(s).

  • EPIX’s TA Score: 5 bullish, 3 bearish.
  • LXRX’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, both EPIX and LXRX are a good buy in the short-term.

Price Growth

EPIX (@Biotechnology) experienced а +2.40% price change this week, while LXRX (@Biotechnology) price change was +9.08% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +11.55%. For the same industry, the average monthly price growth was +17.24%, and the average quarterly price growth was +3.49%.

Reported Earning Dates

EPIX is expected to report earnings on Aug 06, 2025.

LXRX is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+11.55% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LXRX($261M) has a higher market cap than EPIX($75.9M). LXRX YTD gains are higher at: -2.546 vs. EPIX (-4.469). EPIX has higher annual earnings (EBITDA): -27.4M vs. LXRX (-184.29M). LXRX has more cash in the bank: 238M vs. EPIX (114M). EPIX has less debt than LXRX: EPIX (280K) vs LXRX (108M). LXRX has higher revenues than EPIX: LXRX (31.1M) vs EPIX (0).
EPIXLXRXEPIX / LXRX
Capitalization75.9M261M29%
EBITDA-27.4M-184.29M15%
Gain YTD-4.469-2.546176%
P/E RatioN/AN/A-
Revenue031.1M-
Total Cash114M238M48%
Total Debt280K108M0%
FUNDAMENTALS RATINGS
EPIX vs LXRX: Fundamental Ratings
EPIX
LXRX
OUTLOOK RATING
1..100
216
VALUATION
overvalued / fair valued / undervalued
1..100
14
Undervalued
56
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9296
PRICE GROWTH RATING
1..100
6247
P/E GROWTH RATING
1..100
10018
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EPIX's Valuation (14) in the Pharmaceuticals Major industry is somewhat better than the same rating for LXRX (56) in the Biotechnology industry. This means that EPIX’s stock grew somewhat faster than LXRX’s over the last 12 months.

EPIX's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as LXRX (100) in the Biotechnology industry. This means that EPIX’s stock grew similarly to LXRX’s over the last 12 months.

EPIX's SMR Rating (92) in the Pharmaceuticals Major industry is in the same range as LXRX (96) in the Biotechnology industry. This means that EPIX’s stock grew similarly to LXRX’s over the last 12 months.

LXRX's Price Growth Rating (47) in the Biotechnology industry is in the same range as EPIX (62) in the Pharmaceuticals Major industry. This means that LXRX’s stock grew similarly to EPIX’s over the last 12 months.

LXRX's P/E Growth Rating (18) in the Biotechnology industry is significantly better than the same rating for EPIX (100) in the Pharmaceuticals Major industry. This means that LXRX’s stock grew significantly faster than EPIX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EPIXLXRX
RSI
ODDS (%)
N/A
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
85%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 5 days ago
83%
Bullish Trend 2 days ago
84%
Declines
ODDS (%)
Bearish Trend 18 days ago
88%
Bearish Trend 5 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
82%
Aroon
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
EPIX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RRGAX7.34N/A
N/A
DWS RREEF Global Real Estate Secc A
LEGCX49.61N/A
N/A
Columbia Large Cap Growth C
GSWPX23.08N/A
N/A
Goldman Sachs Small/Mid Cap Growth P
LIOTX9.77N/A
N/A
Issachar I
WFSAX26.69N/A
N/A
Allspring Small Company Growth A

EPIX and

Correlation & Price change

A.I.dvisor indicates that over the last year, EPIX has been closely correlated with LOGC. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if EPIX jumps, then LOGC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EPIX
1D Price
Change %
EPIX100%
N/A
LOGC - EPIX
67%
Closely correlated
+3.89%
LXRX - EPIX
34%
Loosely correlated
+8.86%
PCVX - EPIX
31%
Poorly correlated
+2.84%
ELAB - EPIX
30%
Poorly correlated
-5.88%
MREO - EPIX
27%
Poorly correlated
-6.98%
More

LXRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, LXRX has been loosely correlated with PLRX. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if LXRX jumps, then PLRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LXRX
1D Price
Change %
LXRX100%
+8.86%
PLRX - LXRX
41%
Loosely correlated
-2.71%
OCUL - LXRX
38%
Loosely correlated
+0.95%
ABOS - LXRX
38%
Loosely correlated
-0.47%
VCYT - LXRX
37%
Loosely correlated
-1.17%
EPIX - LXRX
34%
Loosely correlated
N/A
More